Tumor antigen-specific CD8-positive T cell (CD8+ T cell; CTL)

Tumor antigen-specific CD8-positive T cells are a crucial cell population in the adaptive immune system, mediating the direct killing of cancer cells that present tumor-associated antigens via major histocompatibility complex class I (MHC-I). These cells recognize tumor antigens through their T cell receptor (TCR), resulting in activation, proliferation, and cytotoxic effector function. In the tumor microenvironment, these cells often exhibit an "exhausted" phenotype—characterized by high expression of inhibitory checkpoint receptors such as PD-1 and CTLA-4, reduced cytokine production (e.g., IFN-γ), and limited proliferative capacity—leading to impaired antitumor activity. Therapies targeting these cells, such as checkpoint inhibitors or engineered adoptive T cell therapies, aim to restore or augment their ability to eliminate tumor cells. This entry describes a cellular population defined by antigen specificity and surface receptor expression, commonly targeted in cancer immunotherapy but not a single molecular target or receptor. Structured information about molecular targets may focus on receptors like PD-1, CTLA-4, or TCR (which are often drug targets), but the clinical and research context regularly refers to antigen-specific CD8+ T cells collectively as a target for immunotherapeutic modulation.

Other names

Cytotoxic T lymphocyteCTLCD8+ T cellKiller T cellCytolytic T cellT-killer cell

Checkpoint inhibition: Blockade of inhibitory signals (PD-1/PD-L1, CTLA-4), restoring T cell effector function. Direct cytotoxicity: Lysis of tumor cells via perforin/granzyme pathway. Cytokine secretion to recruit/activate additional immune effectors. Recognition and killing of antigen-presenting cells expressing tumor antigens via TCR/MHC-I interaction.